This report was first published by Endpoints News. To see the original version, click here
Just a month after announcing a deal with Eli Lilly to work on RNAi drugs for metabolic diseases, SanegeneBio has disclosed a $110 million Series B round to fund its work.
Like a growing number of startups, Sanegene has split its operations between the US and China, with R&D in the Boston area, drug discovery work in Suzhou, China, and a clinical operations center in Shanghai. It currently has about 85 employees. Its deal with Lilly could be worth as much as $1.2 billion.
您已閱讀17%（565字），剩余83%（2728字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。